How Pharmaceutical Executives Can Navigate the Changing Pharmaceutical Landscape

As policy uncertainty, public scrutiny, and shifting regulations redraw the pharmaceutical landscape, business decisions carry more strategic risk than ever. In this Pharmaceutical Executive Peer Exchange, a cross-disciplinary panel examines how executives can plan around pricing uncertainty tied to the Inflation Reduction Act (IRA) and the 2028 wave of physician-administered Part B drug negotiation. Companies also have new considerations to take into account due to Most Favored Nation Pricing (MFN), international reference pricing, and reshoring pressures, creating harder decisions for product launches. To manage that uncertainty, panelists point to scenario planning, cross-functional coordination, and early engagement on policy as ways to build resilience across a range of possible outcomes. The only constant through disruption is keeping patient value at the center of every business and reputational decision.

Key Takeaways

• Recognize how the IRA's differing treatment of small and large molecules affects biosimilar incentives.
• Understand how to communicate contested business decisions to patients and critics by framing them as trust decisions, building narratives that hold up as they travel through both advocates and detractors.
• Assess the FDA's expanding attention to drug pricing and its growing use of artificial intelligence in development and submission review.

DOWNLOAD NOW